Demystifying the results obtained through the use of SGLT-2 inhibitor drugs, used by patients at the Reference Center for Hypertension and Diabetes Rio Verde - Goiás
DOI:
https://doi.org/10.33448/rsd-v12i12.43964Keywords:
Diabetes; ISGLT-2; Glycated hemoglobin; Forxiga.Abstract
Introduction: Due to the increase in glucose excretion of renal sodium-glucose cotransporter 2 (ISGLT-2) inhibitors, there is also a reduction in weight through its glycosuric effect. Objective: To analyze the efficacy of ISGLT-2 based on medical records and glycemic levels according to glycated blood glucose; to verify which medications are most prescribed and to observe poor adherence due to side effects in patients of the CRHD in Rio Verde-GO. Methods: A descriptive observational study was carried out using the medical records of diabetic patients treated at the CRHD as the main means of data collection, identifying and comparing laboratory values based on the different pharmacological conducts performed. And manually organize and group the search results on the Excel platform, where they will later be converted into easy-to-view graphs for the public. Results And Discussion: When analyzing the glycated hemoglobin (HbA1c) of the patients before and after the introduction of the ISGLT-2 class, it was noted that 80% obtained a laboratory improvement and 20% a worsening. The results reveal that 80% had an improvement in glycated hemoglobin, as they presented good adherence to the medication and specific and balanced nutrition for their condition. Conclusion: There is an improvement in glycated hemoglobin in most of the patients treated at the CRHD who are users of iSGLT-2, where the most used medication is Forxiga (Dapaglifozin), which is part of the medications of the SUS network.
References
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023). Evolução dos inibidores do cotransportador de sódio-glicose 2 de um fármaco redutor de glicose para um agente terapêutico fundamental para a síndrome cardiorrenal-metabólica. Endocrinol frontal (Lausanne). 30:14:1111984.
Albarrán, O. G, & Ampudia-Blasco F. J. (2013). [Dapagliflozina, o primeiro inibidor de SGLT-2 no tratamento do diabetes tipo 2]. Med Clin (Barc). 141 Supl 2:36-43. 10.1016/S0025-7753(13)70062-9.
Bianco, H. T. (2021). Effect of sglt-2 inhibitor in diabetic hypertensive patients, when to indicate? Revista brasileira de hipertensão ponto de vista/ /Point of View. Rev Bras Hipertens 28(4):283-7
Chatterjee, S, et al (2018). Type 2 diabetes. The Lancet, 389. https://doi.org/10.1016/S0140-6736(18)30702-5
Camargo, J. L. et al (2004). Glico-hemoglobina (HbA1c): aspectos clínicos e analíticos. Arq Bras Endocrinol Metab 48(4) https://doi.org/10.1590/S0004-27302004000400005
Daily, G (2015). Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. D-Journal, 7, 448-61. 10.1111/1753-0407.12278.
Del Prato, S, Nauck, M, Durán-Garcia, S, Maffei, L, Rohwedder, K, Theuerkauf, A, Parikh (2015).Resposta glicêmica de longo prazo e tolerabilidade da dapagliflozina versus uma sulfonilureia como terapia complementar à metformina em pacientes com diabetes tipo 2: dados de 4 anos. S.Diabetes Obes Metab. 17(6):581-590. 10.1111/dom.12459.
Duarte, R., Araújo, F. & Medina, J. L. (2018) Perfil Clínico da Dapagliflozina: Um Novo Paradigma no Tratamento da Diabetes Tipo 2. Revista Portuguesa de Diabetes, 13(3), 119-132.
Greg, L. P. (2012). Dapagliflozina: uma revisão de seu uso no diabetes mellitus tipo 2. Drogas. Dez 3, 72(17):2289-312. 10.2165/11209910-000000000-00000.
Grupo Interdisciplinar de Padronização da Hemoglobina Glicada - A1C. Hemoglobina glicada. Posicionamento Oficial (versão 2004). A importância da hemoglobina glicada (A1C) para a avaliação do controle glicêmico em pacientes com diabetes mellitus: aspectos clínicos e laboratoriais. Disponível em: http://www.sbpc.org.br/profissional/noticia.diverso.php?id=5&tp=3
Mourão, C. A. et al (2010). Adesão ao uso de medicamentos: algumas considerações. Estudos interdisciplinares em psicologia. Vol.1 Londrina 1(1) p. 96-107
Pancholia, A, et al (2018). Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart Journal, 70. 10.1016/j.ihj.2018.08.022.
Pititto, B, Dias, M, Moura, F, Lamounier, R, Calliari, S, & Bertoluci, M (2023). Metas no tratamento do diabetes. Diretriz Oficial da Sociedade Brasileira de Diabetes. 10.29327/557753.2022-3,
Qiu, H. et al. (2017). Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes/Metabolism Research and Reviews. 33(5), 10.1002/dmrr.2886.
Relatório 524 realizado pela Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde – CONITEC, 2020 disponível em: Relatorio_524_Empagliflozina_e_dapagliflozina_diabetes_mellitus_tipo_2_FINAL.pdf — Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde - CONITEC (www.gov.br)
Rieg, T., & Vallon V. (2018). Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 61(10). 10.1007/s00125-018-4654-7.
Rocha. F.A.C (2007). Da relevância dos estudos observacionais https://doi.org/10.1590/S0482-50042007000200001 . Rev. Bras. Reumatol. 47 (2)
Rodrigues, L.L., Celestino, I.T.P, Santos, F.F, & Oliveira, G.S., et al (2020). Benefício do uso de inibidores do co-transportador renal de sódioglicose 2 (iSGLT- 2) em pacientes com Diabetes Mellitus 2 e Insuficiência Cardíaca. Revista Eletrônica Acervo Saúde / Electronic Journal Collection Health, Vol.12. disponível em: https://doi.org/10.25248/reas.e4349.2020
Silva, L. K., Morais, B. P., Pinto, T. C., Maciel, J. J. R., Rezende, L. G., Moser, L. L. & Carvalho, L. (2021). Mecanismos de desenvolvimento da cetoacidose euglicêmica associados ao uso de inibidores de SGLT2 em pacientes com Diabetes Mellitus. Brazilian Journal of Health Review, Curitiba, 4(5) p. 21025-21038
Sumita, N. M. & Andriolo, A. (2008) A. Importância da hemoglobina glicada no controle do diabetes mellitus e na avaliação de risco das complicações crônicas. Jornal brasileiro de patologia e medicina laboratorial. Medicina Laboratorial • J. Bras. Patol. Med. Lab. 44 (3) • https://doi.org/10.1590/S1676-24442008000300003
Whalen, k, Miller, S, & Onge E.S (2015). The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. ClinTher, 37, p. 1150-1166.
Zelniker, T, & Braunwald, E (2018). Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. Journal of the American College of Cardiology, 72. 10.1016/j.jacc.2018.06.040.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Luan Queiroz Fernandes Pereira; Thamires Ferreira dos Santos; Rodrigo Jacques da Silva; Hortência Thales Padilha Gomes; Júlia Lenza Goulart; João Felipe Cardoso Carvalho ; Lucas Almeida Azevedo Carlos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
